Zynerba Pharmaceuticals (ZYNE) IPO Opens Up 29% Higher

Today's IPO for Zynerba Pharmaceuticals (NASDAQ: ZYNE) opened for trading at $18 after pricing 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

Zynerba Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is evaluating two product candidates, ZYN002 and ZYN001, in five indications. ZYN002, the company's CBD Gel, is the first and only synthetic CBD formulated as a patent protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. ZYN001 will be studied in fibromyalgia and peripheral neuropathic pain.

You May Also Be Interested In

• Viking Holdings (VIK) Announces 44M Share IPO at $21-$25/sh
• Neo-Concept International Group Holdings (NCI) Prices 2.32M Share IPO at $4/sh
• Centuri (CTRI) Opens At $23.75, IPO At $21 (earlier)